The past 200 years in diabetes.

  title={The past 200 years in diabetes.},
  author={Kenneth S. Polonsky},
  journal={The New England journal of medicine},
  volume={367 14},
  • K. Polonsky
  • Published 3 October 2012
  • Medicine
  • The New England journal of medicine
Although scientific advances have led to effective prevention strategies, the pathway to a cure for diabetes has remained elusive. This anniversary article describes progress in the understanding, diagnosis, and management of diabetes during the past 200 years. 

Figures and Tables from this paper

Preface: A New Disease?
Professor Gian Franco Bottazzo delivered the Banting Lecture, in which he announced that diabetes was “a new disease,” based on criteria originally described by Mirko D. Grmek in his classical book about the history of AIDS.
The role of mast cells in type I diabetes mellitus
Scientific Advisor – MD, PhD, Associate Professor Lilian Şaptefraţi Department of Histology, Cytology and Embryology, USMF “Nicolae Testemiţanu”
The Concept and the Epidemiology of Diabetic Nephropathy Have Changed in Recent Years
A stabilization in the rate of end stage kidney disease has been observed in some countries, probably due to the increased awareness by primary care physicians about the prognostic importance of chronic kidney disease (CKD), better control of blood pressure and glycaemia.
Challenge of diabetes mellitus and researchers’ contributions to its control
This study used the content analysis to report the existence of diabetes mellitus and the treatments provided by researchers to control it, and ongoing and future studies in alternative medicine such as vanadium nanoparticles (metal nanoparticles) are promising.
Treatment approach to type 2 diabetes: Past, present and future
Given the raising burden of type 2 DM, the best present strategy that could contribute the most to the reduction of morbidity and mortality should be focused on primary prevention.
An update on the pharmacotherapy options for pediatric diabetes
This review offers an update on current available treatment strategies for type 1 and type 2 diabetes approved for use in children and adolescents, with a strong need for developing new drugs to be used alone or in combination.
Islet cell transplantation.
While islet transplantation is currently generally reserved for adults with type 1 diabetes with severe hypoglycemia or glycemic lability, the possibility of its application to the pediatric population is considered.
100 years of insulin: celebrating the past, present and future of diabetes therapy.
Key accomplishments leading to and building on Banting and Best's landmark description of the discovery of insulin are described, including advancements in the understanding of the role of insulin in diabetes pathophysiology, the molecular characterization of insulin and the clinical use of insulin.
Tracing the proteomic fingerprint of the diabetic aorta?
  • G. Suna, M. Mayr
  • Medicine, Biology
    Circulation. Cardiovascular genetics
  • 2014
Although there is compelling evidence for the association of diabetes mellitus and vascular disease, the underlying pathophysiological mechanisms remain to be elucidated, and advanced glycation end products as well as reactive oxygen species are suggested to be 2 of the major culprits leading to vascular damage.
Cardiovascular Safety Evaluation in the Development of New Drugs for Diabetes Mellitus
The burden of type 2 diabetes mellitus across the United States continues to increase, and the current dramatic increase in the prevalence is a harbinger for increasing cardiovascular morbidity and mortality in the decades ahead.


Effect of a multifactorial intervention on mortality in type 2 diabetes.
In at-risk patients with type 2 diabetes, intensive intervention with multiple drug combinations and behavior modification had sustained beneficial effects with respect to vascular complications and on rates of death from any cause and from cardiovascular causes.
The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.
Irbesartan is renoprotective independently of its blood-pressure-lowering effect in patients with type 2 diabetes and microalbuminuria, and serious adverse events were less frequent among the patients treated with the drug.
Pioglitazone for diabetes prevention in impaired glucose tolerance.
As compared with placebo, pioglitazone reduced the risk of conversion of impaired glucose tolerance to type 2 diabetes mellitus by 72% but was associated with significant weight gain and edema.
[The discovery of insulin].
  • H. Lestradet
  • Medicine
    Bulletin de l'Academie nationale de medecine
  • 1996
It seems necessary, seventy five years later, to reconsider the chronology of the history and put Paolesco but also Collip at the right places much before Banting and Best to whom, by a curious misinterpretation of facts, was attributed the priority of this fundamental discovery.
Molecular mechanisms and clinical pathophysiology of maturity-onset diabetes of the young.
Maturity-onset diabetes of the young (MODY) is a clinically heterogeneous group of disorders characterized by nonketotic diabetes mellitus, an autosomal dominant mode of inheritance, an onset usually
The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group.
Captopril protects against deterioration in renal function in insulin-dependent diabetic nephropathy and is significantly more effective than blood-pressure control alone.
Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes.
A target-driven, long-term, intensified intervention aimed at multiple risk factors in patients with type 2 diabetes and microalbuminuria reduces the risk of cardiovascular and microvascular events by about 50 percent.
HL-A antigens and diabetes mellitus.
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes.
Intensive diabetes therapy has long-term beneficial effects on the risk of cardiovascular disease in patients with type 1 diabetes, and changes between treatment groups remained significant after adjusting for these factors.
Genomics of type 2 diabetes mellitus: implications for the clinician
The current list of genetic loci that are related to T2DM does not seem to offer greater predictive value in determining diabetes risk than do commonly used phenotypic risk factors and family history.